SGMT NASDAQ
Sagimet Biosciences Inc.
1W: -5.0%
1M: +11.5%
3M: +31.6%
YTD: +16.9%
1Y: +104.1%
$7.09
+0.09 (+1.29%)
Weekly Expected Move ±22.8%
$4
$5
$7
$8
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$231.0M
52W Range3.23-11.41
Volume860,427
Avg Volume1,413,617
Beta3.63
Dividend—
Analyst Ratings
Company Info
CEODavid A. Happel
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2023-07-17
Websitesagimet.com
155 Bovet Road
San Mateo, CA 94402
US
San Mateo, CA 94402
US
650-561-8600
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Latest News
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Grauer Andreas | A-Award | 264,759 | $6.44 | 2026-04-20 |
| Grauer Andreas | 0 | — | 2026-04-20 | |
| Rozek Elizabeth | A-Award | 44,000 | — | 2026-02-19 |
| Rozek Elizabeth | A-Award | 88,000 | $5.38 | 2026-02-19 |
| Martins Eduardo Brun | A-Award | 44,000 | — | 2026-02-19 |